NEVVI Medicare utilization intelligence

Compare this medication with others →

Medicare Part D market

Erythromycin/Benzoyl Peroxide

CY2024
Medicare Part D · CY2024 · as published by CMS
Part D Erythromycin/Benzoyl Peroxide Medication
ScopeMedicare Part D prescription drug plans, Medicare Advantage drug plans included, CY2024. A claim is one dispensed fill, refills included. It is not a prescription written and not a patient count.
Sold as
share of claimsprescribers, this brand row
Erythromycin-Benzoyl Peroxide 100.0% 3,311
In CMS's filePublished in every year, CY2020–CY2024, as Erythromycin/Benzoyl Peroxide.
Part D drug cost included in Explore Explore — see the Part D drug cost for this → Gross amount paid at the pharmacy, before manufacturer rebates.
As published by CMS · Medicare Part D Prescribers by Geography and Drug, and by Provider and Drug, CY2024
Market overview
  • Market size 8,099 claims for Erythromycin/Benzoyl Peroxide in CY2024, and 8,717 30-day fills, as CMS publishes them.
  • Growth Down 7.1% year over year; −23.1% over five years (2020 → 2024).
  • Prescribers CMS reports 3,311 prescribers of Erythromycin-Benzoyl Peroxide nationally in CY2024.
  • Where it is prescribed The three largest state markets are New York, California, and Pennsylvania — together 37.2% of claims.
How to read these figures

Claims count dispensed fills, refills included; a claim is not a prescription written and not a patient count. CMS withholds any prescriber with 10 or fewer claims for a brand row, so a prescriber missing from a list is not confirmed absent and every disclosed count is a floor. Totals and prescriber rows come from two separate CMS files that are not built to reconcile, so a prescriber list never adds up to a published total. Shares are computed only against the totals CMS publishes for the place. Prescriber counts belong to one brand row and are never summed across brands, because one clinician can write several brands. All figures are calendar years.

This medication's Overview — its five-year claims trend, and how many state markets publish a total for it — is part of Explore.

See the Part D drug cost

An Explore subscription, $249 a seat a year, opens this medication's Overview, and shows what Medicare Part D spends on it.

It comes with 25 credits a seat a year for Deep Dives, which open the rest.

Subscribe to Explore →

Included in Explore. Part of a Deep Dive.